Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer

• Published in: Cancer chemotherapy and pharmacology Vol. 67; no. 3; pp. 527 - 532
• Main Authors: Kim, Jin Young, Do, Young Rok, Park, Keon Uk, Kim, Jong Gwang, Chae, Yee Soo, Kim, Min Kyoung, Lee, Kyung Hee, Ryoo, Hun Mo, Bae, Sung Hwa, Baek, Jin Ho, Song, Hong Suk
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Berlin/Heidelberg : Springer-Verlag 01.03.2011; Springer-Verlag; Springer; Springer Nature B.V
• Subjects: Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Cancer Research; chemotherapy; cisplatin; Cisplatin - administration & dosage; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Male; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oncology; Original Article; Oxonic Acid - administration & dosage; paclitaxel; Paclitaxel - administration & dosage; Pharmacology. Drug treatments; Pharmacology/Toxicology; Prospective Studies; S-1; stomach neoplasms; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Survival; Tegafur - administration & dosage; Treatment Outcome; Tumors; Chemotherapy; Gastric cancer; S-1; Cisplatin; Paclitaxel; Antineoplastic agent; Multicenter study; Stomach cancer; Triplets; Taxane derivatives; Phase II trial; Advanced stage; Antimitotic; Gastric disease; Platinum II Complexes; Human; Drug combination; Triplet; Patient; Malignant tumor; Alkylating agent; Treatment; Digestive diseases; Combined treatment; Cancer
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-010-1353-6

Objective The present study was conducted to evaluate the efficacy and safety of a combination regimen of S-1, paclitaxel plus cisplatin in patients with advanced gastric cancer. Methods Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 80 mg/m² plus cisplatin 30 mg/m² on days 1, 8 and S-1 35 mg/m² orally twice daily on days 1-14 based on a 3-week cycle. Results Forty-four patients were enrolled in the current study, among whom 38 were assessable for efficacy and all assessable for toxicity. Two complete response and 24 partial responses were confirmed, giving an overall response rate of 59.1%. At a median follow-up of 11.4 months, the median time to progression and median overall survival was 9.4 (95% CI 6.8-12.1) months and 11.2 (95% CI 7.6-14.8) months, respectively. Grade 3/4 neutropenia occurred in 45 events (20.9%) and febrile neutropenia was observed in five events (2.3%). The common non-hematologic toxicity was nausea (grade 1/2, 27.2%) and diarrhea (grade 1/2, 9.0%). Conclusion The combination of S-1, paclitaxel and cisplatin was found to be well tolerated and effective in patients with advanced gastric cancer.